Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    GBP4m

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Electro Optic Systems

    MCap

    AUD647m

    Last close

    AUD3.72

    ▲ 0.37 (11.04%)

    The Metals Company

    MCap

    USD2,637m

    Last close

    USD7.28

    ▲ 0.71 (10.81%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ocugen (OCGN)

Last close As at 14/07/2025

USD1.11

▲ −0.03 (−2.63%)

Market capitalisation

USD325m

Ocugen is a clinical-stage biotechnology company developing novel gene therapies to treat blinding retinal diseases, and its subsidiary is advancing cell therapies for orthopaedic indications.

Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Shankar Musunuri

    CEO

  • Ramesh Ramachandran

    Chief Accounting Officer

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

Edison healthcare quarterly: How to please some of the people some of the time